

Table 3. Treatment efficacy of low-dose versus high-dose somatostatin analogs in patients with acromegaly

Parameter	Before SSA vs low-dose SSA	p1	Low-dose vs high-dose SSA	p2
Random serum GH ($\mu\text{g/L}$)	7.8 [1.2-176]		4.70 [0.29-98.70]	
Median [range]	3.60 [0.10-98.70] n = 71	<0.01	3.35 [0.24-64] n = 43	<0.05
Serum IGF-1 \times ULN	2.8 \pm 1.5		2.3 \pm 1.2	
Mean \pm SD	1.9 \pm 1.2 n = 65	<0.001	1.9 \pm 1.04 n = 41	<0.05
Random serum GH ≤ 2.5 $\mu\text{g/L}$, no./no. evaluable patients (%)	10 / 71 (14.0%) 29 / 71 (40.8%)	<0.001	10 / 43 (23.2%) 19 / 43 (44.1%)	0.06
Any serum GH ≤ 1 $\mu\text{g/L}$, no./no. evaluable patients (%)	2 / 71 (2.8%) 25 / 71 (35.2%)	<0.001	4 / 43 (9.3%) 10 / 43 (23.2%)	NS
Normal serum IGF-1, no./no. evaluable patients (%)	1 / 65 (1.5%) 18 / 65 (27.6%)	<0.001	4 / 41 (9.7%) 7 / 41 (17.0%)	NS
Controlled patients, no./no. evaluable patients (%)	0 / 65 (0.0%) 12 / 65 (18.4%)	<0.001	0 / 41 (0.0%) 5 / 41 (12.1%)	0.059
Optimally controlled patients, no./no. evaluable patients (%)	0 / 65 (0.0%) 13 / 65 (20.0%)	<0.001	0 / 41 (0.0%) 4 / 41 (9.7%)	NS

Controlled patients = random serum GH ≤ 2.5 $\mu\text{g/L}$ and normal IGF-1 for age; optimally controlled patients = any serum GH ≤ 1 $\mu\text{g/L}$ and normal IGF-1 for age; p1 = comparison between values before SSA and those after low-dose SSA; p2 = comparison between values on low-dose SSA and those on high-dose SSA; no.: number; SSA: somatostatin analogs.